Anatomical and Functional Outcome of Single Low Dose Suprachoroidal Triamcinolone Acetonide in Macular Edema Secondary to Non-Infectious Uveitis

Abstract

Background:To study the anatomical and functional outcome following single low dose
suprachoroidal triamcinolone acetonide(LD-SCTA) (2mg) injection in non-infectious
posterior uveitis.Material and Methods:Eleven patients with macular edema more than 300
microns secondary to non-infectious uveitis were included in the study. A single LD-SCTA
(0.5 ml) injection was performed in the study eye with the help of a novel
suprachoroidalmicroneedle (Pricon, IsconSurgicals, Jodhpur, India). The study parameters
were noted at 4- and 12-weeks post LD-SCTA injection.Results:Ten of eleven patients had a
significant decrease in central macular thickness (CMT). The mean CMT measurement at
baseline was 513.6±191.73 m for the ten patient who responded to the treatment, reduced
significantly to 265.1±34.72 m (p<0.003) and 260.6 ±34.72 m (p<0.002) at 4 weeks and 12
weeks respectively. The mean best corrected visual acuity at baseline was 0.84±0.41 logmar
unit which improved to 0.52±0.33 (p<0.001) and 0.25±0.22 (p<0.000)at week 4 and 12
respectively. The mean IOP at baseline recorded was 16.36±2.97 mm of Hg, 19.45±4.80 mm
of Hg (p=0.06) at 4 weeks and 17.27±2.53 mm of Hg(p=0.35) at 12 weeks. One eye which
did not respond to LD-SCTA was a case of recurrent Vogt-Koyanagi-Harada
disease.Conclusion:Single LD-SCTA injection is efficacious in reducing CMT in macular
edema, improving BCVA and controlling the inflammation in non-infectious posterior
uveitis. LD-SCTA can be used as a first line therapy in non-infectious uveitis over other
routes of steroid administration with a favourable outcome and safety profile.